Bioworld Ventures

Language

English

Search History

BIOWORLD

You May Also Like

BIOWORLD

GET A QUOTE

We are passionate about the intersection of biology and technology.

We are experienced global healthcare investor-operators. We contribute venture capital, strategic insight and operational expertise to innovative companies tackling global unmet medical need.

Strategic Insight + Tactical Experience

We have invested in and successfully exited from venture investments and brought products, teams and companies to market in the US, Europe and China.

ABOUT BIOWORLD

From Amino Acids to Action Potentials to Artificial Intelligence.

We dig deep across several disciplines within biotech,medtech, life science tools and digital health. Our interdisciplinary team of engineers,physicians and professional healthcare investors have deep insight across the entire value chain of technology translation, product development and healthcare delivery.

OUR PORTFOLIO

Lexent Bio (acquired by Foundation Medicine, Inc.) is using liquid biopsies, multi-omics and machine learning to determine if a cancer patient is responding to their treatment, earlier than other methods, using low-coverage whole genome sequencing (WGS) and methylation analysis for generation of orthogonal signals for longitudinal tracking.

Senti Bio (NASDAQ: SNTI) designs and optimizes gene circuits, which are created from novel and proprietary combinations of DNA sequences, to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments.

Cardea Bio (acquired by Paragraf) is a Tech + Bio company integrating molecular biology with semiconductors via graphene-based biology-gated sensors. These low-cost, fast, amplification-free sensors can electronically sense biological interactions and kinetics.

CorVista Health is combining digital health and machine learning to develop a novel, non-invasive cardiac diagnostic modality. With an initial focus on heart failure, coronary artery disease, and pulmonary hypertension, the company is advancing the CorVista System, a point-of-care, radiation-free, and exercise-free diagnostic platform.

Arima is a structural genomics company developing technologies to enable read / edit / phenotype access to the in-situ spatial DNA. Arima is developing end-to-end solutions for analysis of the spatial genome in 3D space and an BioAnalytics Platform to customers for unprecedented research insights.

Vena Vitals is developing a soft skin-conforming direct capacitive sensor for measurement of continuous blood pressure. Led by renowned scientist and serial innovator, Prof Michelle Khine, and featured on Netflix's The Gamechangers.

Vigor Medical Systems is developing a digital health platform for managing chronic respiratory diseases. Spun out of Duke University, the company is developing a connected spirometer and HIPAA-Compliant disease management platform to support clinical research, lung diagnostics, and remote disease management.

Yor Labs is developing a proprietary Intracardiac Echocardiography (ICE) system for cardiac electrophysiology and structural heart procedures. It is the only company to have expertise in both the multi-model imaging platform and imaging catheters on a single platform.

MiiCare is developing an AI-enabled platform for remote elderly care that combines companionship, environmental safety and health coaching, utilising a digital health coach, an AI-engine and monitors/alerts via a connected console.

Great Bay Bio is a disruptive AI + biologics development platform that applies AI and other cutting-edge technologies for bioprocessing innovations in CMC

Rare Air are developing a propietary digitally controlled, microfluidic pulmonary drug delivery technology

PORTFOLIO NEWS

SEP 12TH, 2023

CorVista Health Announces FDA Clearance of the Novel CorVista System to Detect the Presence of Cardiac Disease

MAY 3RD, 2022

San Diego’s Cardea Bio nets Gates Foundation grant to uncover COVID, malaria and other diseases via breath

DEC 21ST, 2021

Biotech company Senti Bio to go public via $600 mln SPAC deal

Newsletter: Subscribe to our newsletter to receive the latest industry and portfolio news.

Philosophy: We are keen students of medical history, and believe navigation of the future requires a deep understanding of the past.

Picture Credits: Salk Institute, CA, Cold Spring Harbor Laboratory, NY, Harvard Medical School, MA, and Cambridge MRC-LMB, UK.

Contact Us: Email:[email protected]; Phone:+85291301001